Division of Meridian and Structural Medicine, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea.
Division of Meridian and Structural Medicine, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea ; Korean Medical Science Research Center for Healthy Aging, Pusan National University, Yangsan, Gyeongnam 626-870, Republic of Korea.
Evid Based Complement Alternat Med. 2015;2015:768049. doi: 10.1155/2015/768049. Epub 2015 Apr 7.
PMC-12 is a prescription used in traditional Korean medicine that consists of a mixture of four herbal medicines, Polygonum multiflorum, Rehmannia glutinosa, Polygala tenuifolia, and Acorus gramineus, which have been reported to have various pharmacological effects on age-related neurological diseases. In the present study, we investigated whether PMC-12 improves cognitive deficits associated with decreased neuroinflammation in an amyloid-β-(Aβ-) induced mouse model and exerts the antineuroinflammatory effects in lipopolysaccharide-(LPS-) stimulated murine BV2 microglia. Intracerebroventricular injection of Aβ 25-35 in mice resulted in impairment in learning and spatial memory, whereas this was reversed by oral administration of PMC-12 (100 and 500 mg/kg/day) in dose-dependent manners. Moreover, PMC-12 reduced the increase of Aβ expression and activation of microglia and astrocytes in the Aβ 25-35-injected brain. Furthermore, quantitative PCR data showed that inflammatory mediators were significantly decreased by administration of PMC-12 in Aβ-injected brains. Consistent with the in vivo data, PMC-12 significantly reduced the inflammatory mediators in LPS-stimulated BV2 cells without cell toxicity. Moreover, PMC-12 exhibited anti-inflammatory properties via downregulation of ERK, JNK, and p38 MAPK pathways. These findings suggest that the protective effects of PMC-12 may be mediated by its antineuroinflammatory activities, resulting in the attenuation of memory impairment; accordingly, PMC-12 may be useful in the prevention and treatment of AD.
PMC-12 是一种传统韩方药物，由何首乌、地黄、远志和石菖蒲等四种草药混合而成，已被报道具有多种针对与年龄相关的神经退行性疾病的药理学作用。在本研究中，我们研究了 PMC-12 是否能改善与神经炎症降低相关的认知缺陷，这种认知缺陷是由淀粉样蛋白-β（Aβ）诱导的小鼠模型引起的，并在脂多糖（LPS）刺激的小鼠 BV2 小胶质细胞中发挥抗炎作用。Aβ25-35 脑室内注射导致小鼠学习和空间记忆受损，而口服 PMC-12（100 和 500mg/kg/天）以剂量依赖性方式逆转了这种情况。此外，PMC-12 减少了 Aβ25-35 注射脑内 Aβ 表达的增加和小胶质细胞和星形胶质细胞的激活。此外，定量 PCR 数据显示，在 Aβ 注射的脑中，炎症介质的表达显著降低。与体内数据一致，PMC-12 在 LPS 刺激的 BV2 细胞中没有细胞毒性的情况下显著降低了炎症介质的表达。此外，PMC-12 通过下调 ERK、JNK 和 p38 MAPK 通路表现出抗炎特性。这些发现表明，PMC-12 的保护作用可能是通过其抗炎作用介导的，从而减轻记忆损伤；因此，PMC-12 可能对 AD 的预防和治疗有用。
